193 related articles for article (PubMed ID: 11358853)
21. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
[TBL] [Abstract][Full Text] [Related]
22. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.
Yang C; Cai J; Wang Q; Tang H; Cao J; Wu L; Wang Z
Gynecol Oncol; 2012 Feb; 124(2):325-34. PubMed ID: 22005523
[TBL] [Abstract][Full Text] [Related]
24. Molecular cloning and characterization of a novel human BTB domain-containing gene, BTBD10, which is down-regulated in glioma.
Chen J; Xu J; Ying K; Cao G; Hu G; Wang L; Luo C; Lou M; Mao Y; Xie Y; Lu Y
Gene; 2004 Sep; 340(1):61-9. PubMed ID: 15556295
[TBL] [Abstract][Full Text] [Related]
25. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
26. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization.
Shridhar V; Sen A; Chien J; Staub J; Avula R; Kovats S; Lee J; Lillie J; Smith DI
Cancer Res; 2002 Jan; 62(1):262-70. PubMed ID: 11782386
[TBL] [Abstract][Full Text] [Related]
27. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer.
Liu Y; Emilion G; Mungall AJ; Dunham I; Beck S; Le Meuth-Metzinger VG; Shelling AN; Charnock FM; Ganesan TS
Oncogene; 2002 Jan; 21(3):387-99. PubMed ID: 11821951
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.
Toyooka S; Fukuyama Y; Wistuba II; Tockman MS; Minna JD; Gazdar AF
Clin Cancer Res; 2002 Jul; 8(7):2292-7. PubMed ID: 12114433
[TBL] [Abstract][Full Text] [Related]
29. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
30. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
32. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
33. MSJ-1, a new member of the DNAJ family of proteins, is a male germ cell-specific gene product.
Berruti G; Perego L; Borgonovo B; Martegani E
Exp Cell Res; 1998 Mar; 239(2):430-41. PubMed ID: 9521861
[TBL] [Abstract][Full Text] [Related]
34. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer.
Chien J; Staub J; Hu SI; Erickson-Johnson MR; Couch FJ; Smith DI; Crowl RM; Kaufmann SH; Shridhar V
Oncogene; 2004 Feb; 23(8):1636-44. PubMed ID: 14716297
[TBL] [Abstract][Full Text] [Related]
35. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
36. Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma.
Ko JM; Chan PL; Yau WL; Chan HK; Chan KC; Yu ZY; Kwong FM; Miller LD; Liu ET; Yang LC; Lo PH; Stanbridge EJ; Tang JC; Srivastava G; Tsao SW; Law S; Lung ML
Mol Cancer Res; 2008 Apr; 6(4):592-603. PubMed ID: 18403638
[TBL] [Abstract][Full Text] [Related]
37. CTp11, a novel member of the family of human cancer/testis antigens.
Zendman AJ; Cornelissen IM; Weidle UH; Ruiter DJ; van Muijen GN
Cancer Res; 1999 Dec; 59(24):6223-9. PubMed ID: 10626816
[TBL] [Abstract][Full Text] [Related]
38. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
[TBL] [Abstract][Full Text] [Related]
39. Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.
Nixdorf S; Grimm MO; Loberg R; Marreiros A; Russell PJ; Pienta KJ; Jackson P
Cancer Lett; 2004 Nov; 215(2):209-20. PubMed ID: 15488640
[TBL] [Abstract][Full Text] [Related]
40. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
